Mail this to me:

Roche

TECENTRIQ® atezolizumab | AVASTIN® bevacizumab

COMPLETE DOSAGE REGIMEN GUIDE FOR 1L UNRESECTABLE HCC

A combination therapy with consistent, Q3W infusions[1,2]



Indication:

Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

In combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

IV=intravenous; Q3W=every 3 weeks.

TECENTRIQ® atezolizumab | AVASTIN® bevacizumab

Roche

TECENTRIQ DOSING AND ADMINISTRATION
Unresectable or metastatic HCC

Recommended dosage schedule for HCC[1,2]

Recommended dosage	Duration of therapy
TECENTRIQ can be administered at: • 840 mg IV q2w or • 1200 mg IV q3w or • 1680 mg* IV q4w Bevacizumab† is administered at 15 mg/kg q3w	Until disease progression or unacceptable toxicity
TECENTRIQ infusion time • 60-minute initial infusion • 30-minute subsequent infusions if initial infusion is tolerated	

Dosing information for bevacizumab is based on the IMbrave150 trial; TECENTRIQ was administered q3w in IMbrave150.

HCC=hepatocellular carcinoma; IV=intravenous; q2w=every 2 weeks; q3w=every 3 weeks; q4w=every 4 weeks.

*Administered with two 840-mg vials of TECENTRIQ.

†Refer to the Prescribing Information for bevacizumab prior to initiation.

- **Administer TECENTRIQ prior to bevacizumab when given on the same day**
- TECENTRIQ can be administered with or without a sterile, nonpyrogenic, low-protein binding in-line filter (pore size of 0.2–0.22 micron)
- Do not administer TECENTRIQ as an IV push or bolus
- Do not co-administer other drugs through the same IV line
- Administer bevacizumab as an IV infusion
- First infusion of bevacizumab: administer infusion over 90 minutes
- Subsequent infusions: administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated
- Refer to the Prescribing Information for bevacizumab for bevacizumab dosage modifications for specific adverse reactions. No dose reductions for bevacizumab are recommended

IV=intravenous; Q3W=every 3 weeks.

TECENTRIQ® atezolizumab | AVASTIN® bevacizumab

Roche

PREPARATION OF TECENTRIQ[1]

1. INSPECT

Visually inspect drug product for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard the vial if the solution is cloudy, discolored, or visible particles are observed. Do not shake the vial.

2. WITHDRAW

- Select the appropriate vial(s) based on the prescribed dose
- Withdraw the required volume of TECENTRIQ from the vial(s)
- Dilute to a final concentration between 3.2 and 16.8 mg/mL in a polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO) infusion bag containing 0.9% sodium chloride injection, USP
- Dilute with only 0.9% sodium chloride injection, USP

3. MIX

Mix diluted solution by gentle inversion. Do not shake.

4. DISCARD

Discard used or empty vials of TECENTRIQ.

STORAGE OF TECENTRIQ[1]

This product does not contain a preservative. Administer immediately once prepared. If diluted TECENTRIQ infusion solution is not used immediately, it can be stored either

- At room temperature for no more than 6 hours from the time of preparation. This includes room-temperature storage of the infusion in the infusion bag and time for administration of infusion, or
- Under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 24 hours from time of preparation
- Do not freeze. Do not shake

TECENTRIQ® atezolizumab | AVASTIN® bevacizumab

Roche

AVASTIN DOSING AND ADMINISTRATION[2]

Recommended dosage schedule for HCC

The recommended dosage is 15 mg/kg intravenously after administration of 1,200 mg of atezolizumab intravenously on the same day, every 3 weeks until disease progression or unacceptable toxicity.

PREPARATION OF BEVACIZUMAB/AVASTIN

1. INSPECT

Visually inspect vial for particulate matter and discoloration prior to preparation for administration. Discard vial if solution is cloudy, discolored or contains particulate matter.

2. WITHDRAW

- Use appropriate aseptic technique.
- Use sterile needle and syringe to prepare Avastin.
- Withdraw necessary amount of Avastin and dilute in a total volume of 100 mL of 0.9% Sodium Chloride Injection, USP. DO NOT ADMINISTER OR MIX WITH DEXTROSE SOLUTION.

3. MIX

Mix diluted solution by gentle inversion. Do not shake.

4. DISCARD

Discard any unused portion left in a vial, as the product contains no preservatives.

STORAGE OF AVASTIN[2]

- Store diluted Avastin solution at 2°C to 8°C (36°F to 46°F) for up to 8 hours.
- No incompatibilities between Avastin and polyvinylchloride or polyolefin bags have been observed.

ADMINISTRATION

- Administer as an intravenous infusion.
- First infusion: Administer infusion over 90 minutes.
- Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated.

Mail this to me:

Roche

TECENTRIQ®
atezolizumab

AVASTIN®
bevacizumab

REFERENCES
1. TECENTRIQ Prescribing Information. Roche Products (India) Pvt. Ltd.
2. Avastin (bevacizumab) Prescribing Information. Roche Products (India) Pvt. Ltd.

Kindly use the QR code / click on the link for the latest Prescribing Information (PI). For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

http://bit.ly/Roche_Tecentriq_Avastin_PI

M-IN-00002583

Marketed in India by: Roche Products (India) Pvt. Ltd. 146-B, 166 A, Unit No. 7, 8, 9, 8th Floor, R City Office, R City Mall, Lal Bahadur Shastri Marg, Ghatkopar, Mumbai - 400 086 Maharashtra; Tel No. +91 22 50457300; Fax No. +91 22 50457301